This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
CJC-1295 DAC (2 mg Vial)
CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analogue with albumin-binding technology that extends its half-life to approximately 6–8 days[1][2]. By stimulating pulsatile growth hormone (GH) release while preserving natural GH rhythms, CJC-1295 DAC can elevate GH levels 2–10 fold and IGF-1 levels 1.5–3 fold in human studies[3]. Benefits may include enhanced muscle growth and recovery, improved fat metabolism, better sleep quality, and anti-aging effects through sustained GH/IGF-1 axis activation[4][5].
Quick Reference
What is CJC-1295 DAC?
Research overview based on the cited scientific literature.
• Goal: Elevate endogenous GH and IGF-1 levels to support muscle growth, fat metabolism, recovery, and anti-aging research[4][5].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality and efficacy.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw[8].
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is CJC-1295 DAC studied?
CJC-1295 DAC is a modified 30-amino-acid GHRH analog conjugated to a Drug Affinity Complex (DAC) that covalently binds to serum albumin after injection[1]. This albumin binding dramatically extends the peptide’s half-life from minutes to approximately 6–8 days, enabling once-weekly dosing[2]. CJC-1295 binds to GHRH receptors on pituitary somatotrope cells, amplifying GH synthesis and pulsatile release. Importantly, it elevates basal GH levels while preserving the natural rhythm of GH pulses — the frequency and amplitude remain intact[11]. Clinical trials demonstrate sustained 2–10 fold increases in GH and 1.5–3 fold increases in IGF-1, with elevated IGF-1 persisting for up to 28 days after multiple doses[3].
What does the research report about CJC-1295 DAC?
Observations from preclinical and clinical literature.
• Sustained elevation of GH and IGF-1 levels supporting muscle growth, recovery, and lean body composition[4][5].
• Reference [12] reports a tesamorelin trial in people with HIV-associated abdominal fat accumulation; it does not provide direct evidence that CJC-1295 reduces visceral fat.
• Improved sleep quality — GHRH analogs may have somnogenic effects, increasing deep slow-wave sleep[6].
• Preserves natural GH pulsatility unlike exogenous GH administration[11].
• Common side effects may include transient flushing, injection-site reactions, water retention, or headache; serious adverse effects are uncommon at standard doses[7].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on CJC-1295 DAC?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
